首页> 外文期刊>The Indian journal of medical research. >Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study
【24h】

Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study

机译:十二个月固定持续时间的世卫组织多药性麻风病多药疗法:基于阿格拉地区的队列研究复发的发生率

获取原文
获取原文并翻译 | 示例
       

摘要

Background & objectives: The reported low relapse rates after 24 months multidrug therapy (MDT) for multibacillary leprosy (MB) led to the recommendation of reducing duration of therapy to 12 months. However, only a few reports exist on long term follow up data after 12 months fixed duration therapy (FDT). The present study was done to assess the incidence of relapse in MB leprosy patients after 12 months treatment.Methods: The leprosy patients detected in field surveys during 2001-2006 in Agra district, Uttar Pradesh, India, were put on WHO-MDT and followed up for treatment completion, relapse, reactions and development of disability. The assessment was done clinically by following up the patients until January 2011. Data collected were analyzed for risk and survival analysis.Results: The incidence of relapse was found to be 1.97/100 person years of follow up. The incidence of relapse by age (34 yr vs >34 yr), sex (male vs female), delay in detection (<36 months vs >36 months) and smear status (smear +ve vs -ve) was not found to be significantly different but patients with no nerve involvement were observed to have significantly higher relapses than those with three or more nerve involvement (P<0.05). Similarly, borderline-borderline and BB with reaction (BB/BBR) patients were observed to have significantly high relapses than among those with borderline tuberculoid or BT with reaction (BT/BTR) or borderline lipromatous/lepromatouseuritic (BL/LL/N) type of leprosy Interpretation & conclusion: From the observations in the study, it can be suggested that relapses occur in 12 months FDT and almost as much as reported in 24 months FDT for MB leprosy. Although, early relapses may be due to insufficient treatment, late relapses may be due to persistent dormant mycobacteria. However, a study relating to immunological response of treatment and change in immunological profile relating to the occurrence of relapses and its ch'nical correlates may suggest better information on causes of relapses.
机译:背景与目的:据报道,多药性麻风病(MB)的24个月多药治疗(MDT)后复发率低,因此建议将治疗时间缩短至12个月。但是,只有12个月的固定持续时间治疗(FDT)后长期随访数据的报道。本研究旨在评估12个月治疗后MB麻风病患者的复发率。方法:将2001-2006年在印度北方邦阿格拉地区进行实地调查发现的麻风病患者接受WHO-MDT随访,用于完成治疗,复发,反应和残疾发展。通过对患者进行随访直至2011年1月进行临床评估。对收集的数据进行了风险和生存分析。结果:复发的发生率为1.97 / 100人/年的随访。未发现按年龄(34岁对> 34岁),性别(男性对女性),检测延迟(<36个月对> 36个月)和涂片状态(涂片+ ve与-ve)的复发率。差异有统计学意义,但观察到无神经受累的患者复发率明显高于神经受累三或更多的患者(P <0.05)。同样,观察到交界-边界线和BB伴反应(BB / BBR)患者的复发率显着高于交界性结核或BT伴反应(BT / BTR)或交界性或原发/麻风/神经炎(BL / LL / N)患者。 )麻风的类型解释和结论:从研究中的观察结果可以看出,MB麻风病的复发发生在FDT的12个月,几乎是24个月的FDT。尽管早期复发可能是由于治疗不足引起的,但晚期复发可能是由于持续休眠的分枝杆菌引起的。然而,一项有关治疗的免疫反应和与复发的发生及其相关的免疫学特征变化有关的研究可能会提示有关复发原因的更好信息。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号